Clinical Effectiveness of HBV Vaccination in HIV-Positive Patients

In an observational cohort study that showed a high incidence of hepatitis B virus infection after HIV diagnosis, HBV vaccination was effective only in a subgroup with HBV surface antibody titers ≥10 IU/L.

Current guidelines recommend that all HIV-positive patients be vaccinated against hepatitis B virus (HBV) infection. Several studies have focused on HIV patients’ serologic response to the HBV vaccine, but its effectiveness against clinical illness is less well characterized. Now, using data from participants enrolled in the United States Military HIV Natural History Study from 1986 through 2004, researchers have attempted to define the clinical effectiveness.

Of 4586 patients in the cohort, 1853 met the inclusion criteria of no HBV infection and no prior HBV vaccination upon documentation of HIV seropositivity: 881 never received the HBV vaccine, and 972 received at least one dose of it after HIV diagnosis (542 of the 972 received at least …

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Clinical Effectiveness of HBV Vaccination in HIV-Positive Patients

Topics

Reviewing Author